The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Advances Day 2017 | The future of predicting outcomes for patients with MPNs: a patient knowledge bank
The discovery of various molecular risk factors for myeloproliferative neoplasms (MPNs) has revolutionized the way in which doctors diagnose these diseases, and the way that they determine the prognosis. Speaking from the Myeloproliferative Neoplasms Advances Day 2017, London, UK, Tony Green, MD, PhD, of the University of Cambridge, Cambridge, UK, discusses some of the most important molecular discoveries that have changed the field of MPN diagnosis, such as the JAK2 V617F mutation. He also proposes a way in which the presence or absence of these mutations, combined with clinical data and outcomes, could be used to generate a patient knowledge bank, used to accurately predict new patient outcomes.
